Inhibrx Biosciences (INBX) EBITDA (2023 - 2026)
Inhibrx Biosciences (INBX) posted quarterly EBITDA of -$30.9 million for Q4 2025, up 38.06% year-over-year from -$22.4 million in Q4 2024, and up 8.54% quarter-over-quarter from -$33.8 million in Q3 2025.
Powered by 
Analysis
Inhibrx Biosciences (INBX) EBITDA (2023 - 2026) Analysis & Trends
Inhibrx Biosciences (INBX) has reported EBITDA for 3 consecutive years, with -$30.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, EBITDA rose 38.06% year-over-year to -$30.9 million; the TTM figure through Dec 2025 stood at -$135.0 million (up 59.26% YoY), while the FY2025 annual figure was -$135.0 million, up 59.26% from the prior year.
- EBITDA advanced to -$30.9 million in Q4 2025 per INBX's latest filing, from -$33.8 million in the prior quarter.
- Across five years, EBITDA topped out at -$27.4 million in Q2 2025 and bottomed at -$160.9 million in Q2 2024.
- Historically, EBITDA has averaged -$58.4 million across 3 years, with a median of -$45.8 million in 2023.
- Annual changes were most pronounced in 2024 — EBITDA plunged 289.22% — and 2025, when it jumped 82.98%.
- Inhibrx Biosciences' EBITDA stood at -$88.3 million in 2023, then jumped by 43.45% to -$49.9 million in 2024, then surged by 38.06% to -$30.9 million in 2025.
- Business Quant data shows INBX's EBITDA at -$30.9 million in Q4 2025, -$33.8 million in Q3 2025, and -$27.4 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Inhibrx Biosciences | 1.92 Bn | 1.92 Bn | - | -32.15 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -32.15 Mn |
| Dec 31, 2025 | -30.92 Mn |
| Sep 30, 2025 | -33.81 Mn |
| Jun 30, 2025 | -27.39 Mn |
| Mar 31, 2025 | -42.90 Mn |
| Dec 31, 2024 | -49.93 Mn |
| Sep 30, 2024 | -46.80 Mn |
| Jun 30, 2024 | -160.90 Mn |
| Mar 31, 2024 | -73.83 Mn |
| Dec 31, 2023 | -88.29 Mn |
| Sep 30, 2023 | -45.83 Mn |
| Jun 30, 2023 | -41.34 Mn |